Article

Detection of recurrence in glioma: a comparative prospective study between Tc-99m GHA SPECT and F-18 FDG PET/CT.

Department of Nuclear Medicine, Medical College Kolkata, Kolkata, India.
Clinical nuclear medicine (Impact Factor: 3.92). 08/2011; 36(8):650-5. DOI:10.1097/RLU.0b013e318217aee0
Source: PubMed

ABSTRACT Early and correct diagnosis of tumor recurrence and its differentiation from therapy-related changes is crucial for prompt and adequate management of glioma patients. The purpose of this study was to compare the efficacies of Tc-99m glucoheptonate (GHA) single photon emission tomography (SPECT) and F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in detection of recurrence in patients with glioma.
A total of 90 patients with histopathologically proven glioma who had suspicion of recurrence clinically or on magnetic resonance imaging were evaluated using Tc-99m GHA SPECT and FDG PET/CT. Combination of clinical follow-up, repeat imaging, and biopsy (when available) was taken as gold standard.
On the basis of gold standard, 59 patients were positive and 31 were negative for tumor recurrence. The sensitivity, specificity, and accuracy of GHA SPECT were 85%, 97%, and 89%, respectively, whereas those of FDG PET/CT were 70%, 97%, and 80%, respectively. On subgroup analysis, GHA SPECT performed better than FDG PET/CT in all grades except for grade II gliomas, where both were equally effective. In all, 15 patients had intermodality discordance, with GHA SPECT being correct in 13 of them.
GHA SPECT appears to be a better imaging modality than FDG PET/CT for detection of recurrent gliomas.

0 0
 · 
1 Bookmark
 · 
174 Views
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Although positron emission tomography (PET) may be credited with providing the impetus for the new clinical interest in functional neuroimaging and currently is an increasingly important imaging tool for noninvasive assessment of brain tumors, single-photon emission tomography (SPET) has offered an alternative technique with the relative advantages of lower price and wide availability. Brain SPET has been proven useful in the differentiation of tumor recurrence from radiation necrosis, in the non-invasive assessment of gliomas and meningiomas aggressiveness, in differentiating neoplastic from non neoplastic intracerebral haemorrhage, in monitoring treatment response and estimating patients' prognosis. Thus, SPET may still have a role in the diagnosis and characterization of brain tumors. Future comparative studies between SPET and PET or latest magnetic resonance based neuroimaging techniques are warranted.
    Hellenic journal of nuclear medicine 06/2012; 15(2):89-91. · 0.68 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Objective: This study aimed to evaluate and compare the role of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for diagnosing recurrence in patients with glioma. Methods: Thirty patients with histopathologically proven glioma (glioblastoma multiforme, 14; grade III, 6; grade II, 8; and grade I, 2), who presented with clinical and/or imaging suspicion of recurrence were prospectively evaluated. They were primarily treated with surgery and radiotherapy with or without chemotherapy. Each patient underwent 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT within a span of 15 days. Images were evaluated qualitatively and quantitatively by 2 experienced nuclear medicine physicians in consensus. Histopathology and/or clinical/imaging follow-up were used as reference standard. Results: Based on reference standard, 22 patients were positive and 8 were negative for recurrence. 99mTc-GH SPECT/CT was positive for recurrence in 22 and negative in 8 patients. 18F-FDOPA PET/CT scan was positive for recurrence in 23 and negative in 7 patients. Sensitivity, specificity, and accuracy were 86.4%, 62.5%, and 80% for 99mTc-GH SPECT/CT and 100%, 87.5%, and 96% for 18F-FDOPA PET/CT, respectively. No significant difference was found between 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT overall (P = 1.00), as well as for low-grade (P = 0.250) or high-grade tumors (P = 0.50). Significant correlation was noted between tumor-brain of 99mTc-GH with both tumor-striatum (r = 0.371; P = 0.044) and tumor-cerebellum ratio of 18F-FDOPA (r = 0.369; P = 0.045). Conclusions: For detection of recurrence in glioma patients, 99mTc-GH SPECT/CT is not inferior to 18F-FDOPA PET/CT and can be used as a lowcost alternative.
    Clinical nuclear medicine 04/2013; · 3.92 Impact Factor

Full-text

View
80 Downloads
Available from
Jul 14, 2012